1. Analyst View
2. Research Methodology
3. Market Overview
4. Key Market Drivers
4.1 Improved Routine Immunization
4.2 New Vaccine Introduction
4.3 High Investments
4.4 Support from Government and NGOs
5. Emerging Trends
5.1 Cancer Vaccines: Gaining Popularity
5.2 Collaborations in Vaccine Industry
5.3 Grants: Raising Support
6. Industry Performance and Future Trends
7. Major Vaccine Segments
7.1 Basic Pediatrics
7.2 Enhanced Pediatrics
7.3 Proprietary Pediatrics
7.4 Adult Vaccines
8. Pediatric Vaccines
8.1 Pneumococcal
8.2 Polio
8.3 Varicella
8.4 Meningococcal
8.5 Rotavirus
8.6 DTP
8.7 Measles, Mumps & Rubella (MMR)
8.8 Tuberculosis
9. Adult/Travel & Therapeutic Vaccines
9.1 Hepatitis B
9.2 Malaria
9.3 Yellow Fever
9.4 Rabies
9.5 Japanese Encephalitis
9.6 Typhoid
9.7 West Nile
9.8 HIV
9.9 Cancer
9.10 Influenza
10. Key Geographical Markets
10.1 US
10.1.1 Market Overview
10.1.2 Key Players
10.1.3 Product Portfolio
10.2 Europe
10.2.1 Market Overview
10.2.2 Key Players
10.2.3 Product Portfolio
10.3 China
10.3.1 Market Overview
10.3.2 Key Players
10.3.3 Product Portfolio
10.4 India
10.4.1 Market Overview
10.4.2 Key Players
10.4.3 Product Portfolio
10.5 Japan
10.5.1 Market Overview
10.5.2 Key Players
10.5.3 Product Portfolio
10.6 Brazil
10.6.1 Market Overview
10.6.2 Key Players
10.6.3 Product Portfolio
11. Investment Risk in Vaccine Industry
11.1 High R&D Cost
11.2 Lack of Infrastructure for Trials and Manufacturing
11.3 Vaccine Supply
11.4 Ineffective Distribution
12. Key Mergers & Acquisitions
13. Key Vaccine Brands Forecast to 2012
14. Competitive Landscape
14.1 Vaccine Majors
14.1.1 Sanofi-Aventis
14.1.2 Novartis
14.2 Biotech-focused Vaccine Companies
14.2.1 GSK
14.2.2 Pfizer
14.3 Domestic-focused Vaccine Companies
14.3.1 Merck & Co.
